Revenue increased by 11% to $1.4 billion; up 8% on a constant currency basis GAAP gross margin up 290 bps to 62.2%; non-GAAP gross margin up 290 ...
Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Brett Sandercock, Chief Financial Officer, plans to ...
Resmed said its Chief Financial Officer will retire in May and announced plans to acquire a startup with an FDA de novo ...
Zacks Investment Research on MSN
ResMed (RMD) Reports Q3 Earnings: What Key Metrics Have to Say
For the quarter ended March 2026, ResMed (RMD) reported revenue of $1.43 billion, up 10.8% over the same period last year. EPS came in at $2.86, compared to $2.37 in the year-ago quarter. The reported ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Acquisition supports Resmed’s growth in virtual care, expands access to diagnosis, and enhances the digital experience for patients and providers SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Resmed ...
Zacks Investment Research on MSN
ResMed (RMD) surpasses Q3 earnings and revenue estimates
ResMed (RMD) came out with quarterly earnings of $2.86 per share, beating the Zacks Consensus Estimate of $2.79 per share. This compares to earnings of $2.37 per share a year ago. These figures are ...
Expands ResMed’s sleep management software solution, will help sleep labs and physicians more efficiently guide patients into and through diagnosis to long-term treatment Diagnostic management ...
Please note, Resmed does not use outside phone lines to access the earnings call, the call is accessible via the above webcast link only. A replay of the earnings webcast will be accessible on ...
Resmed will buy Noctrix Health, the Pleasanton, Calif.-based developer of the Nidra Tonic Motor Activation therapy for ...
Q3 reiterated FY 2026 gross margin range “62% to 63%” (CFO Sandercock), consistent with Q2’s updated FY 2026 gross margin range.
SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2026 on Thursday, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results